Aspirin and Renal Disease Progression in Patients With Type 2 Diabetes (LEDA)

Clinical Trial ID NCT02895113

Rank	Title	Journal	Year	PubWeight™‹?›
1	Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.	Diabetes Care	2004	75.82
2	Platelet activation and atherothrombosis.	N Engl J Med	2007	6.18
3	Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline.	Ann Intern Med	2013	4.32
4	Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects.	Thromb Res	1980	2.68
5	Thromboxane blockade reduces blood pressure and progression of renal failure independent of endothelin-1 in uremic rats.	Prostaglandins Leukot Essent Fatty Acids	2004	0.80
6	Aspirin and renal insufficiency progression in patients with atrial fibrillation and chronic kidney disease.	Int J Cardiol	2016	0.76
7	Effects of nonsteroidal anti-inflammatory drugs on prostacyclin and thromboxane in the kidney.	Pharmacology	2003	0.75
8	Antiplatelet agents for chronic kidney disease.	Cochrane Database Syst Rev	2022	0.75